Biofrontera Secures FDA Nod for Ameluz in Superficial Basal Cell Carcinoma — Biofrontera Inc.

Event summary

FDA approved Ameluz for superficial basal cell carcinoma (sBCC) on September 14, 2026, making it the first PDT drug approved for skin cancer in the U.S.
The approval expands Ameluz's addressable market to include ~540,000–720,000 sBCC cases annually in the U.S.
Phase 3 trial showed 66% complete response rate for Ameluz vs. 5% for placebo.
Biofrontera plans Q4 2026–Q1 2027 launch through existing commercial channels.

The big picture

This approval solidifies Biofrontera's leadership in photodynamic therapy for dermatology, addressing a significant unmet need in non-surgical skin cancer treatment. The expansion into sBCC complements its existing actinic keratosis indication, positioning Ameluz as a versatile tool in medical dermatology. With ~3.6 million BCC cases diagnosed annually in the U.S., this represents a substantial market opportunity.

What we're watching

Market Penetration: How Biofrontera will leverage its existing customer base to drive adoption of the new sBCC indication.
Competitive Positioning: Whether Ameluz can establish itself as the preferred non-surgical option for sBCC.
Revenue Growth: The pace at which the sBCC approval translates into meaningful revenue contributions.